Guanabenz

Guanabenz
	File:Guanabenz.svg
	File:Guanabenz sf.png
Systematic (IUPAC) name
	2-(2,6-dichlorobenzylidene)hydrazinecarboximidamide
Clinical data
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a686003
Pregnancy; category	US: C (Risk not ruled out) ; ;
Pharmacokinetic data
Protein binding	90%
Half-life	6 hours
Identifiers
CAS Registry Number	5051-62-7
ATC code	None
PubChem	CID 5702063
DrugBank	DB00629 7px
ChemSpider	4642445 7px
UNII	GGD30112WC 7px
KEGG	D04375 7px
ChEMBL	CHEMBL420 7px
Chemical data
Formula	C8H8Cl2N4
Molecular mass	231.081 g/mol
	SMILES Clc1cccc(Cl)c1\C=N\N=C(/N)N;
	InChI InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+ 7px ; Key:WDZVGELJXXEGPV-YIXHJXPBSA-N 7px ;
14px (what is this?) (verify)

</th></tr></th></tr>

Guanabenz (pronounced GWAHN-a-benz, sold under the trade name Wytensin) is an alpha agonist of the alpha-2 adrenergic receptor that is used as an antihypertensive drug. It is used to treat high blood pressure (hypertension).^[1]^[2]

The most common side effects during guanabenz therapy are dizziness, drowsiness, dry mouth, headache and weakness.

Guanabenz can make one drowsy or less alert, therefore driving or operating dangerous machinery is not recommended.

References

^ Walker BR, Hare LE, Deitch MW (1982). "Comparative antihypertensive effects of guanabenz and clonidine". The Journal of International Medical Research 10: 6–14. PMID 7037502.
^ Bonham AC, Trapani AJ, Portis LR, Brody MJ (1984). "Studies on the mechanism of the central antihypertensive effect of guanabenz and clonidine". Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension 2: S543–6.

Lua error in package.lua at line 80: module 'Module:Buffer' not found.